Salyamova Lyudmila, Oleynikov Valentin, Donetskaya Natalia, Vdovkin Alexander, Chernova Angelina, Avdeeva Irina
Therapy Department, Penza State University, 440026 Penza, Russia.
Regional Clinical Hospital n/a N.N. Burdenko, 440026 Penza, Russia.
Diagnostics (Basel). 2024 Mar 11;14(6):588. doi: 10.3390/diagnostics14060588.
The purpose of the study was to identify factors characterizing a decrease in LV global systolic function in patients with ST-segment elevation myocardial infarction (STEMI) after revascularization using cardiac magnetic resonance imaging (MRI)-based ischemic injury pattern and laboratory parameters sensu left ventricular global systolic function. A total of 109 STEMI patients were examined. The patients underwent contrast-enhanced cardiac MRI with a 1.5 Tesla GE SIGNA Voyager (GE HealthCare, Chicago, IL, USA) on the 7th-10th days from the onset of the disease. According to cardiac MRI analysis, the patients were divided into the following groups with regard to left ventricular ejection fraction (LVEF) values: Group 1-patients with LVEF ≥ 50%; group 2-patients with mildly reduced LVEF 40-49%; group 3-patients with low LVEF < 40%. A predominance of most parameters of the ischemic injury pattern was noted in patients with mildly reduced and low LVEF versus patient group with LVEF ≥ 50%. Some risk factors for a decrease in LVEF < 50% systolic function in STEMI patients after revascularization were revealed: male gender; time from the onset of the anginal attack to revascularization; coronary artery status; several LV parameters; ischemic injury characteristics; natriuretic peptide and troponin I levels.
本研究的目的是利用基于心脏磁共振成像(MRI)的缺血损伤模式和反映左心室整体收缩功能的实验室参数,确定ST段抬高型心肌梗死(STEMI)患者血运重建后左心室整体收缩功能下降的特征因素。共检查了109例STEMI患者。患者在发病后第7至10天接受了使用1.5特斯拉GE SIGNA Voyager(美国伊利诺伊州芝加哥市GE医疗集团)进行的对比增强心脏MRI检查。根据心脏MRI分析,根据左心室射血分数(LVEF)值将患者分为以下几组:第1组-LVEF≥50%的患者;第2组-LVEF轻度降低至40%-49%的患者;第3组-LVEF<40%的患者。与LVEF≥50%的患者组相比,LVEF轻度降低和降低的患者中缺血损伤模式的大多数参数占优势。揭示了STEMI患者血运重建后LVEF<50%收缩功能下降的一些危险因素:男性;从心绞痛发作到血运重建的时间;冠状动脉状况;几个左心室参数;缺血损伤特征;利钠肽和肌钙蛋白I水平。